The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex

International Journal of Neuropsychopharmacology

Volumn 9, Issue 3, 2006, Pages 287-296

  Chertkow, Yael ^a,b   Weinreb, Orly ^b   Youdim, Moussa B H ^b   Silver, Henry ^a  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Antipsychotics; GABA; Negative symptoms; Schizophrenia; SSRI

Indexed keywords

4 AMINOBUTYRIC ACID; CLOZAPINE; FLUVOXAMINE; GLUTAMATE DECARBOXYLASE 67; HALOPERIDOL; PROTEIN KINASE C BETA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA MICROARRAY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; FRONTAL CORTEX; GABAERGIC SYSTEM; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC SCREENING; LONG TERM CARE; MALE; MOLECULAR DYNAMICS; MONOTHERAPY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; CLOZAPINE; DRUG THERAPY, COMBINATION; FLUVOXAMINE; FRONTAL LOBE; GAMMA-AMINOBUTYRIC ACID; GLUTAMATE DECARBOXYLASE; HALOPERIDOL; ISOENZYMES; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A;

EID: 33646889956     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145705005626     Document Type: Article

References (58)

1. Adams BW, Moghaddam B (2001). Effect of clozapine, haloperidol, or M100907 on phencyclidine-activated glutamate efflux in the prefrontal cortex. Biological Psychiatry 50, 750-757.
2. Ago Y, Nakamura S, Baba A, Matsuda T (2005). Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex. Neuropsychopharmacology 30, 43-51.
3. Bai O, Chlan-Fourney J, Bowen R, Keegan D, Li XM (2003). Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs. Journal of Neuroscience Research 71, 127-131.
4. Baldessarini RJ, Centorrino F, Flood JG, Volpicelli SA, Huston-Lyons D, Cohen BM (1993). Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 9, 117-124.
5. Battaini F (2001). Protein kinase C isoforms as therapeutic targets in nervous system disease states. Pharmacological Research 44, 353-361.
6. Benes FM, Vincent SL, Marie A, Khan Y (1996). Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75, 1021-1031.
7. Blum PB, Mann JJ (2002). The GABAergic system in schizophrenia. International Journal of Neuropsychopharmacology 5, 159-179.
8. Brandon NJ, Delmas P, Kittler JT, McDonald BJ, Sieghart W, Brown DA, Smart TG, Moss SJ (2000). GABAA receptor phosphorylation and functional modulation in cortical neurons by a protein kinase C-dependent pathway. Journal of Biological Chemistry 275, 38856-38862.
9. Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, Wong DT, Perry KW (2002). Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berlin) 160, 353-361.
10. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001). Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annual Review of Pharmacology and Toxicology 41, 237-260.
11. Chong VZ, Young LT, Mishra RK (2002). cDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment. Journal of Neurochemistry 82, 1533-1539.
12. Daniel WA, Syrek M, Wojcikowski J (1999). The influence of selective serotonin reuptake inhibitors on the plasma and brain pharmacokinetics of the simplest phenothiazine neuroleptic promazine in the rat. European Neuropsychopharmacology 9, 337-344.
13. Dean B, Opeskin K, Pavey G, Hill C, Keks N (1997). Changes in protein kinase C and adenylate cyclase in the temporal lobe from subjects with schizophrenia. Journal of Neural Transmission 104, 1371-1381.
14. Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J (2001). A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clinical Neuropharmacology 24, 43-49.
15. Di Cara B, Samuel D, Salin P, Kerkerian-Le Goff L, Daszuta A (2003). Serotonergic regulation of the GABAergic transmission in the rat basal ganglia. Synapse 50, 144-150.
16. Feng J, Cai X, Zhao J, Yan Z (2001). Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons. Journal of Neuroscience 21, 6502-6511.
17. Freeman WM, Brebner K, Lynch WJ, Robertson DJ, Roberts DC, Vrana KE (2001). Cocaine-responsive gene expression changes in rat hippocampus. Neuroscience 108, 371-380.
18. Gao XM, Hashimoto T, Cooper TB, Tamminga CA (1997). The dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration. Journal of Neural Transmission 104, 97-104.
19. Goff DC, Evins AE (1998). Negative symptoms in schizophrenia: neurobiological models and treatment response. Harvard Review of Psychiatry 6, 59-77.
20. Goff DC, Henderson DC, Evins AE, Amico E (1999). A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biological Psychiatry 45, 512-514.
21. Guidotti A, Pesold C, Costa E (2000). New neurochemical markers for psychosis: a working hypothesis of their operation. Neurochemical Research 25, 1207-1218.
22. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, Haroutunian V, Fienberg AA (2001). Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proceedings of the National Academy of Sciences USA 98, 4746-4751.
23. Hartter S, Wetzel H, Hiemke C (1992). Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. Clinical Chemistry 38, 2082-2086.
24. Horowitz JM, Goyal A, Ramdeen N, Hallas BH, Horowitz AT, Torres G (2003). Characterization of fluoxetine plus olanzapine treatment in rats: a behavior, endocrine, and immediate-early gene expression analysis. Synapse 50, 353-364.
25. Ichikawa J, Meltzer HY (1999). Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. European Archives of Psychiatry and Clinical Neuroscience 249, 90-98.
26. Igarashi K, Kasuya F, Fukui M, Usuki E, Castagnoli Jr. N (1995). Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP + found in rat brain following ip administration of HP. Life Sciences 57, 2439-2446.
27. Kalkman HO, Loetscher E (2003). GAD67: the link between the GABA-deficit hypothesis and the dopaminergic- and glutamatergic theories of psychosis. Journal of Neural Transmission 110, 803-812.
28. Kontkanen O, Toronen P, Lakso M, Wong G, Castren E (2002). Antipsychotic drug treatment induces differential gene expression in the rat cortex. Journal of Neurochemistry 83, 1043-1053.
29. Nadon R, Shoemaker J (2002). Statistical issues with microarrays: processing and analysis. Trends in Genetics 18, 265-271.
30. Nogues X (1997). Protein kinase C, learning and memory: a circular determinism between physiology and behaviour. Progress in Neuropsychopharmacology and Biological Psychiatry 21, 507-529.
31. Poisbeau P, Cheney MC, Browning MD, Mody I (1999). Modulation of synaptic GABAA receptor function by PKA and PKC in adult hippocampal neurons. Journal of Neuroscience 19, 674-683.
32. Pongrac J, Middleton FA, Lewis DA, Levitt P, Mimics K (2002). Gene expression profiling with DNA microarrays: advancing our understanding of psychiatric disorders. Neurochemical Research 27, 1049-1063.
33. Qin ZH, Zhang SP, Weiss B (1994). Dopaminergic and glutamatergic blocking drugs differentially regulate glutamic acid decarboxylase mRNA in mouse brain. Brain Research. Molecular Brain Research 21, 293-302.
34. Quackenbush J (2001). Computational analysis of microarray data. Nature Reviews Genetics 2, 418-427.
35. Sands SA, de Blas AL, Chronwall BM (1998). Dopamine D2 receptor effects on GABA(A) receptor expression may modify melanotrope peptide release. Peptides 19, 397-401.
36. Silva A, Kumar S, Pereda A, Faber DS (1995). Regulation of synaptic strength at mixed synapses: effects of dopamine receptor blockade and protein kinase C activation. Neuropharmacology 34, 1559-1565.
37. Silver H (2003). Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. International Clinical Psychopharmacology 18, 305-313.
38. Silver H, Aharon N, Kaplan A (2003a). Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms. Schizophrenia Bulletin 29, 541-546.
39. Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M (2000). Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. International Clinical Psychopharmacology 15, 257-261.
40. Silver H, Feldman P, Bilker W, Gur RC (2003b). Working memory deficit as a core neuropsychological dysfunction in schizophrenia. American Journal of Psychiatry 160, 1809-1816.
41. Silver H, Nassar A (1992). Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biological Psychiatry 31, 698-704.
42. Silver H, Nassar A, Aharon N, Kaplan A (2003c). The onset and time course of response of negative symptoms to add-on fluvoxamine treatment. International Clinical Psychopharmacology 18, 87-92.
43. Silver H, Shmugliakov N (1998). Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study. Journal of Clinical Psychopharmacology 18, 208-211.
44. Silver H, Youdim MB (2000). MAO-A and MAO-B activities in rat striatum, frontal cortex and liver are unaltered after long-term treatment with fluvoxamine and desipramine. European Neuropsychopharmacology 10, 125-128.
45. Strauss ME (1993). Relations of symptoms to cognitive deficits in schizophrenia. Schizophrenia Bulletin 19, 215-231.
46. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood 3rd WH, Donovan DM, Webster M, Freed WJ, Becker KG (2001). Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Research Bulletin 55, 641-650.
47. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA (2000). Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Archives of General Psychiatry 57, 237-245.
48. Wang HY, Markowitz P, Levinson D, Undie AS, Friedman E (1999). Increased membrane-associated protein kinase C activity and translocation in blood platelets from bipolar affective disorder patients. Journal of Psychiatric Research 33, 171-179.
49. Wang X, Zhong P, Yan Z (2002). Dopamine D4 receptors modulate GABAergic signaling in pyramidal neurons of prefrontal cortex. Journal of Neuroscience 22, 9185-9193.
50. Wassef A, Baker J, Kochan LD (2003). GABA and schizophrenia: a review of basic science and clinical studies. Journal of Clinical Psychopharmacology 23, 601-640.
51. Weigmann H, Hartter S, Maehrlein S, Kiefer W, Kramer G, Dannhardt G, Hiemke C (2001). Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography. Journal of Chromatography. B: Biomedical Sciences and Applications 759, 63-71.
52. Woo TU, Whitehead RE, Melchitzky DS, Lewis DA (1998). A subclass of prefrontal gamma-aminobutyric acid axon terminals are selectively altered in schizophrenia. Proceedings of the National Academy of Sciences USA 95, 5341-5346.
53. Yan Z (2002). Regulation of GABAergic inhibition by serotonin signaling in prefrontal cortex: molecular mechanisms and functional implications. Molecular Neurobiology 26, 203-216.
54. Yasui-Furukori N, Kondo T, Mihara K, Inoue Y, Kaneko S (2004). Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia. Psychopharmacology (Berlin) 171, 223-227.
55. 2+-dependent proteolysis. Journal of Neurochemistry 65, 1622-1630.
56. Zernig G, De Wit H, Telser S, Nienhusmeier M, Wakonigg G, Sturm K, Berger I, Kemmler G, Saria A (2004). Subjective effects of slow-release bupropion versus caffeine as determined in a quasi-naturalistic setting. Pharmacology 70, 206-215.
57. Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP (2000). Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 23, 250-262.
58. Zink M, Schmitt A, May B, Muller B, Demirakca T, Braus DF, Henn FA (2004). Differential effects of long-term treatment with clozapine or haloperidol on GABAA receptor binding and GAD67 expression. Schizophrenia Research 66, 151-157.